Highly selective inhibition of histone demethylases by de novo macrocyclic peptides.Kawamura, A., Munzel, M., Kojima, T., Yapp, C., Bhushan, B., Goto, Y., Tumber, A., Katoh, T., King, O.N., Passioura, T., Walport, L.J., Hatch, S.B., Madden, S., Muller, S., Brennan, P.E., Chowdhury, R., Hopkinson, R.J., Suga, H., Schofield, C.J.
(2017) Nat Commun 8: 14773-14773
- PubMed: 28382930
- DOI: 10.1038/ncomms14773
- Primary Citation of Related Structures:
- PubMed Abstract:
- Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity.
Ng, S.S.,Kavanagh, K.L.,McDonough, M.A.,Butler, D.,Pilka, E.S.,Lienard, B.M.,Bray, J.E.,Savitsky, P.,Gileadi, O.,von Delft, F.,Rose, N.R.,Offer, J.,Scheinost, J.C.,Borowski, T.,Sundstrom, M.,Schofield, C.J.,Oppermann, U.
(2007) Nature 448: 87
- Substrate- and cofactor-independent inhibition of histone demethylase KDM4C.
Leurs, U.,Lohse, B.,Rand, K.D.,Ming, S.,Riise, E.S.,Cole, P.A.,Kristensen, J.L.,Clausen, R.P.
(2014) ACS Chem. Biol. 9: 2131
The JmjC histone demethylases (KDMs) are linked to tumour cell proliferation and are current cancer targets; however, very few highly selective inhibitors for these are available. Here we report cyclic peptide inhibitors of the KDM4A-C with selectivi ...
The JmjC histone demethylases (KDMs) are linked to tumour cell proliferation and are current cancer targets; however, very few highly selective inhibitors for these are available. Here we report cyclic peptide inhibitors of the KDM4A-C with selectivity over other KDMs/2OG oxygenases, including closely related KDM4D/E isoforms. Crystal structures and biochemical analyses of one of the inhibitors (CP2) with KDM4A reveals that CP2 binds differently to, but competes with, histone substrates in the active site. Substitution of the active site binding arginine of CP2 to N-ɛ-trimethyl-lysine or methylated arginine results in cyclic peptide substrates, indicating that KDM4s may act on non-histone substrates. Targeted modifications to CP2 based on crystallographic and mass spectrometry analyses results in variants with greater proteolytic robustness. Peptide dosing in cells manifests KDM4A target stabilization. Although further development is required to optimize cellular activity, the results reveal the feasibility of highly selective non-metal chelating, substrate-competitive inhibitors of the JmjC KDMs.
Department of Chemistry, Graduate School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo 113-0033, Japan.,JST, CREST, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-0033, Japan.,Structural Genomics Consortium, University of Oxford, Old Road Campus Roosevelt Drive, Headington OX3 7DQ, UK.,Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK.,Chemistry Research Laboratory, Department of Chemistry, University of Oxford, 12 Mansfield Road, Oxford OX1 3TA, UK.,Division of Cardiovascular Medicine, Radcliffe Department of Medicine, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, UK.